



**Press release – June 14, 2011**

## **Abstral® launches in Canada**

**Uppsala, Sweden, June 14 2011 – Through its local partner, Orexo now initiates marketing and sales of the pain treatment Abstral in Canada.**

In 2008, ProStrakan, who markets Abstral in Europe and the U.S., licensed its rights in the Canadian market to Paladin Labs Inc., which now launches the treatment of breakthrough pain in cancer patients in the Canadian market.

Paladin Labs is a specialty pharmaceutical company focused on marketing of innovative drugs in Canada. The company also markets the pain products Tridural®, Metadol® and Pennsaid®.

In February 2011 Abstral was approved by Health Canada, the Canadian Government Department with responsibility for public health. Canada is one of the top 10 pharmaceutical markets in the world.

### **For further information, please contact:**

Anders Lundström, President and CEO, Orexo AB

Tel: +46 706 67 22 66

Email: [anders.lundstrom@orexo.com](mailto:anders.lundstrom@orexo.com)

### **About Abstral**

Abstral is a rapidly-disintegrating, sublingual (under the tongue) formulation of fentanyl. The product is approved for the treatment of breakthrough pain in patients receiving opioid analgesics for underlying chronic cancer pain. The total market for treatment of cancer breakthrough pain is estimated to about 1.5 billion USD.

### **About Orexo**

Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo's registered products are Abstral® for the treatment of break through cancer pain, sold by Kyowa Hakko Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill Edluar™, sold by Meda in the USA, as well as two products for the diagnosis of *Helicobacter pylori* which are being marketed by the subsidiary Kibion. More information can be found at [www.orexo.com](http://www.orexo.com).

#### **Note:**

*This is information that Orexo AB (publ.) is required to disclose pursuant to the Swedish Securities Markets Act. The information was provided for public release on June 14, 2011 at 2:00p.m. CET.*